ARK Invest's position in SDGR, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 2,413,204 | $74.4M | 3.77% | #11 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | ARKG | Buy | Added | 4,717 | $83K |
| 2026-08-13 | ARKG | Buy | Added | 28,179 | $520K |
| 2026-08-12 | ARKG | Buy | Added | 9,356 | $174K |
| 2026-08-11 | ARKG | Buy | Added | 16,060 | $300K |
| 2026-08-10 | ARKG | Buy | Added | 1,044 | $20K |
| 2026-08-07 | ARKG | Buy | Added | 29,970 | $544K |
| 2026-08-06 | ARKG | Buy | Added | 48,584 | $865K |
| 2025-12-18 | ARKG | Buy | Added | 103,106 | $1.8M |
| 2025-12-15 | ARKG | Buy | Added | 14,043 | $256K |
| 2025-12-12 | ARKG | Buy | Added | 54,917 | $991K |
| 2025-12-11 | ARKG | Buy | Added | 36,554 | $663K |
| 2025-04-30 | ARKG | Sell | Trimmed | 5,721 | $147K |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery…
See SDGR's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open SDGR on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.